Marina Beltrami Moreira, MD
Hematology & Oncology · Columbus, OHNPI 1699127373
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (50.7%), food and beverage and education — rather than concentrated in one kind of arrangement. Argenx US, Inc. accounts for 65.6% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $1,963, more than ten times the $13 reported in 2022. That places this record below the midpoint for hematology & oncology clinicians in OH, where the typical reported total is $2,354.
Across 16 payments — averaging $133.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$1K
- Sanofi$377
- Genentech USA, Inc.$138
- Novo Nordisk$122
- Seagen Inc.$83
- Fresenius Kabi USA, LLC$13
Across 1 payment — averaging $31,371 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$31K
What the payments were for
- Travel & lodging$1,07851%
- Food & beverage$96745%
- Education$834%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 8 | $1,396 |
| Sanofi | 4 | $377 |
| Genentech USA, Inc. | 1 | $138 |
| Novo Nordisk | 1 | $122 |
| Seagen Inc. | 1 | $83 |
| Fresenius Kabi USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,128 in reported general payments places this provider in the 45th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $8,547 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Columbus
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Sameh MikhailColumbus$135K
- Erin BertinoColumbus$73K
- Mark KnappColumbus$67K
- Kathleen KerriganColumbus$47K
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Saulius GirniusMontgomery$707K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.